| scholarly article | Q13442814 |
| P2093 | author name string | H Tsunoda | |
| M Noguchi | |||
| N Sato | |||
| M Nishida | |||
| T Kubo | |||
| Y Morishita | |||
| Y Takimoto | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clear cell carcinoma | Q18556242 |
| heterozygosity | Q124059385 | ||
| cyst | Q193211 | ||
| P304 | page(s) | 7052-7056 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary | |
| P478 | volume | 60 |
| Q90146216 | A Systematic Review and Bioinformatics Study on Genes and micro-RNAs Involving the Transformation of Endometriosis into Ovarian Cancer |
| Q82126701 | A case of ovarian mucinous adenocarcinoma in a premenarcheal girl |
| Q24610484 | ARID1A mutations in endometriosis-associated ovarian carcinomas |
| Q99637155 | ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis |
| Q53363710 | Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways. |
| Q34528553 | Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. |
| Q55230761 | Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. |
| Q43967752 | An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway |
| Q39239168 | Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation |
| Q36975191 | Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells |
| Q54221402 | Association between ovarian cancer and advanced endometriosis. |
| Q36729509 | BAG3 elevation inhibits cell proliferation via direct interaction with G6PD in hepatocellular carcinomas |
| Q58129865 | Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis |
| Q40468392 | Cancer-Associated Mutations in Endometriosis without Cancer. |
| Q37637147 | Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy |
| Q36094353 | Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity |
| Q37820754 | Classification of ovarian carcinomas based on pathology and molecular genetics |
| Q39375621 | Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary |
| Q26749280 | Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives |
| Q92645925 | Clear-Cell Carcinoma of the Ovary with Bilateral Breast Metastases |
| Q91742964 | Clinical implication for endometriosis associated with ovarian cancer |
| Q51035195 | Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. |
| Q92316519 | Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review |
| Q64969004 | Current Status of Patient-Derived Ovarian Cancer Models. |
| Q34305434 | Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. |
| Q36868408 | Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis |
| Q42855628 | Endocervical‐like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation |
| Q49884536 | Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development |
| Q34033619 | Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects |
| Q27003273 | Endometriosis and ovarian cancer: links, risks, and challenges faced |
| Q40290088 | Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses |
| Q55452757 | Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute. |
| Q37406235 | Endometriosis research using capture microdissection techniques: Progress and future applications |
| Q26768656 | Endometriosis-associated Malignancy |
| Q36790454 | Endometriosis-associated ovarian cancer: a review of pathogenesis |
| Q39200003 | Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary |
| Q92200712 | Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study |
| Q28292742 | Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma |
| Q37624069 | Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. |
| Q36962482 | GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. |
| Q37094076 | Genetic and molecular changes in ovarian cancer |
| Q35136686 | Genetics and genomics of endometriosis |
| Q24533776 | Genomewide linkage study in 1,176 affected sister pair families identifies a significant susceptibility locus for endometriosis on chromosome 10q26. |
| Q34005179 | Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q36129961 | Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis |
| Q37701494 | Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis |
| Q36178164 | Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer |
| Q36285026 | Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma |
| Q36224971 | Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma |
| Q34382719 | Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions |
| Q36751649 | MUC1 in endometriosis and ovarian cancer |
| Q90266334 | Machine Learning Classifiers for Endometriosis Using Transcriptomics and Methylomics Data |
| Q36774429 | Malignant transformation of residual endometriosis following hysterectomy and bilateral salpingo-oophorectomy in a female patient from a family with hereditary non-polyposis colorectal cancer |
| Q26784516 | Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma |
| Q37967486 | Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form. |
| Q35140600 | Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm |
| Q37293672 | Molecular pathogenesis of endometrial and ovarian cancer |
| Q58704366 | Nucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic Option |
| Q34350701 | Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles |
| Q82238526 | Ovarian cancer |
| Q37645709 | Ovarian cancer in endometriosis: clinical and molecular aspects |
| Q37621318 | Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management |
| Q37017056 | Ovarian cancer stroma: pathophysiology and the roles in cancer development |
| Q35545814 | Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| Q37982940 | Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features |
| Q36026090 | Ovarian clear cell adenocarcinoma: a continuing enigma |
| Q35098091 | Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis |
| Q24596679 | Pathogenesis and pathophysiology of endometriosis |
| Q36469640 | Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms |
| Q37101060 | Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications |
| Q34771886 | Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development |
| Q37622105 | Precursors of endometrial and ovarian carcinoma |
| Q35108906 | Progesterone action in breast, uterine, and ovarian cancers |
| Q42125233 | Pten, a protean tumor suppressor |
| Q27009487 | Recent concepts of ovarian carcinogenesis: type I and type II |
| Q34643587 | Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma |
| Q37040282 | Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis |
| Q24651331 | Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts |
| Q37375092 | Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. |
| Q30391301 | Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer |
| Q37224282 | Targeting Src in endometriosis-associated ovarian cancer |
| Q36608043 | Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma |
| Q26785614 | The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life |
| Q38787667 | The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded |
| Q58796878 | The Endometriotic Tumor Microenvironment in Ovarian Cancer |
| Q36785983 | The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer |
| Q55054543 | The Role of Oxidative Stress and Membrane Transport Systems during Endometriosis: A Fresh Look at a Busy Corner. |
| Q36236523 | The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero |
| Q30240709 | The disparate origins of ovarian cancers: pathogenesis and prevention strategies. |
| Q36742613 | The endometriotic tissue lining the internal surface of endometrioma: hormonal, genetic, epigenetic status, and gene expression profile. |
| Q37385514 | The mammalian ovary from genesis to revelation |
| Q36953384 | The search for genes contributing to endometriosis risk |
| Q58122541 | Weighted Gene Co-expression Network Analysis of Endometriosis and Identification of Functional Modules Associated With Its Main Hallmarks |
| Q88213478 | [Endometriosis-related ovarian tumors] |
| Q80152213 | [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy] |
| Q39820138 | p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. |
Search more.